ClinicalThought™
Interact with experts and peers.

Recent Posts

10 of 64 Shown
  • The Impact of New Options for DAA-Experienced Patients With HCV

    Jordan J. Feld MD, MPH - 11/16/2017
    With the approvals of SOF/VEL/VOX and GLE/PIB, what is the new management approach for DAA-experienced patients with HCV infection?
  • How Recent Drug Approvals Have Affected First-line HCV Treatment

    Nancy Reau MD, FAASLD, AGAF - 11/15/2017
    What parameters now qualify a patient infected with HCV for shortened first-line therapy?
  • How New Data From the 2017 DC Hepatology Meeting Shed Light on the Clinical Benefits of HCV DAAs

    Jordan J. Feld MD, MPH - 11/14/2017
    Studies presented at the 2017 hepatology meeting in Washington, DC, sought to provide answers to questions surrounding mortality and HCC risk in patients with HCV who achieved SVR with DAA therapy. Here’s my take.
  • Do HCV DAAs Increase HCC Recurrence Risk or Not?

    Paul Y. Kwo MD - 5/25/2017 8 comments / Last Comment: 6/28/2017
    Here’s my take on new data from EASL 2017.
  • EASL 2017: Emerging Therapies for Genotype 3 HCV

    Nancy Reau MD, FAASLD, AGAF - 5/12/2017 6 comments / Last Comment: 6/23/2017
    Genotype 3 HCV infection is concerning, not just because of its natural history but also because of its potential role in reinfection. New data from EASL offer promise for the treatment of this challenging patient population.
  • Why I am Encouraged by Data on NASH Management From the 2016 Boston Hepatology Meeting

    Brent A. Neuschwander-Tetri MD - 3/10/2017
    The treatment of NASH has challenges not seen in patients with HCV infection, but new trends are emerging.
  • How Data From the 2016 Boston Hepatology Meeting Will Influence Future HCV Patient Management

    Mark S. Sulkowski MD - 1/31/2017 2 comments / Last Comment: 4/24/2017
    The 2016 hepatology meeting in Boston offered future solutions to some of my most vexing patient challenges.
  • Hepatitis B Reactivation: Sometimes Scratching the Surface May Be Better Than Getting to the Core

    Jordan J. Feld MD, MPH - 1/24/2017 3 comments / Last Comment: 5/6/2017
    Does the need for HBV reactivation screening vary by the potency of immunosuppressive therapy? Here’s my take.
  • How Recent Guideline Updates on HBV Screening in HCV-Infected DAA Recipients Affect Clinical Practice

    Norah Terrault MD, MPH - 11/23/2016 3 comments / Last Comment: 10/31/2017
    How do recent AASLD/IDSA updates on HBV screening change nonspecialist and specialist management of HCV patients? Here’s my take.
  • Weighing the Treatment Options for Genotype 3 HCV Infection in Cirrhotics

    Mark S. Sulkowski MD - 2/25/2016 3 comments / Last Comment: 4/11/2016
    In my practice, it is the patient with cirrhosis and genotype 3 HCV infection who causes me to pause and carefully consider the patient’s treatment options.
10 of 64 Shown
Show 10 More
Loading...